We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where Chimerix, Inc. (NASDAQ:CMRX) stands against the other stocks. One of the ...

DUBLIN and DURHAM, N.C., March 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix"), today announced the companies have ...

Chimerix cell biologist Phiroze Sethna draws samples to help him begin to grow and study new cells in his anti-viral research in 2011. Chimerix’s value has plummeted from $2.5 billion last summer to ...

DURHAM, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of ...

Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out in 2026. Company has high risk of loss despite ...

- Small Business Administration Rules that SIGA Technologies is Not a Small Business, Rendering It Ineligible for BARDA Contract RESEARCH TRIANGLE PARK, NC, November 7, 2010 - Chimerix, Inc., a ...

Chimerix’s first approved drug had several high-profile setbacks and ended up with a much narrower regulatory nod than initially hoped. Now the company is selling rights to that drug to Emergent ...

DURHAM, NC, February 14, 2011 – Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F ...

Shares of Chimerix Inc. shot up 14.4% in premarket trading Monday, after the biopharmaceutical company said it will sell exclusive rights to its smallpox treatment, including Tembexa, to Emergent ...

Investors are furious about management's plan to sell its most valuable asset in order to chase a lackluster oncology program. Under the terms of the agreement, Chimerix will receive $225 million when ...

Social media campaigns for "compassionate use" access to drugs still in clinical trials got a big boost yesterday. The mother of Josh Hardy, a now-8-year-old boy suffering with cancer for nearly all ...

The biopharma's shares imploded after the company's lead product candidate missed its primary endpoint in a late-stage study. The company suggested that these disappointing results may have been ...